On Tuesday, Editas Medicine Inc (NASDAQ: EDIT) opened lower -0.82% from the last session, before settling in for the closing price of $1.22. Price fluctuations for EDIT have ranged from $1.12 to $11.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 135.89% annually for the last half of the decade. Company’s average yearly earnings per share was noted -35.17% at the time writing. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
In an organization with 265 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 68.00%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -35.17% per share during the next fiscal year.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Check out the current performance indicators for Editas Medicine Inc (EDIT). In the past quarter, the stock posted a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.87 million. That was inferior than the volume of 2.57 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 21.48%. Additionally, its Average True Range was 0.13.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 3.00%, which indicates a significant decrease from 20.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.33% in the past 14 days, which was lower than the 81.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9026, while its 200-day Moving Average is $3.9569. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $1.2567. Second resistance stands at $1.3033. The third major resistance level sits at $1.3567. If the price goes on to break the first support level at $1.1567, it is likely to go to the next support level at $1.1033. Assuming the price breaks the second support level, the third support level stands at $1.0567.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are currently 82,548K shares outstanding in the company with a market cap of 99.88 million. Presently, the company’s annual sales total 78,120 K according to its annual income of -153,220 K. Last quarter, the company’s sales amounted to 60 K and its income totaled -62,140 K.
